Rhumbline Advisers Coherus Bio Sciences, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q4 2024

A detailed history of Rhumbline Advisers transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 155,201 shares of CHRS stock, worth $172,273. This represents 0.0% of its overall portfolio holdings.

Number of Shares
155,201
Previous 149,509 3.81%
Holding current value
$172,273
Previous $155,000 38.06%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025
BUY
$0.67 - $1.71 $3,813 - $9,733
5,692 Added 3.81%
155,201 $214,000
Q3 2024

Nov 12, 2024
SELL
$0.99 - $1.8 $5,341 - $9,711
-5,395 Reduced 3.48%
149,509 $155,000
Q2 2024

Aug 01, 2024
BUY
$1.58 - $2.51 $39,880 - $63,354
25,241 Added 19.47%
154,904 $267,000
Q1 2024

May 09, 2024
BUY
$2.02 - $3.14 $10,069 - $15,652
4,985 Added 4.0%
129,663 $309,000
Q4 2023

Feb 08, 2024
SELL
$1.59 - $3.85 $4,766 - $11,542
-2,998 Reduced 2.35%
124,678 $415,000
Q3 2023

Nov 09, 2023
SELL
$3.74 - $5.45 $349,357 - $509,089
-93,411 Reduced 42.25%
127,676 $477,000
Q2 2023

Aug 08, 2023
BUY
$3.79 - $8.3 $58,040 - $127,106
15,314 Added 7.44%
221,087 $944,000
Q1 2023

May 11, 2023
BUY
$5.89 - $10.52 $59,836 - $106,872
10,159 Added 5.19%
205,773 $1.41 Million
Q4 2022

Feb 14, 2023
BUY
$5.69 - $10.07 $48,410 - $85,675
8,508 Added 4.55%
195,614 $1.55 Million
Q3 2022

Nov 10, 2022
BUY
$7.17 - $13.87 $48,777 - $94,357
6,803 Added 3.77%
187,106 $1.8 Million
Q2 2022

Aug 11, 2022
BUY
$5.86 - $13.23 $89,089 - $201,135
15,203 Added 9.21%
180,303 $1.31 Million
Q1 2022

May 12, 2022
BUY
$10.92 - $16.41 $98,192 - $147,558
8,992 Added 5.76%
165,100 $2.13 Million
Q4 2021

Feb 10, 2022
SELL
$15.81 - $18.99 $25,928 - $31,143
-1,640 Reduced 1.04%
156,108 $2.49 Million
Q3 2021

Nov 12, 2021
SELL
$12.68 - $17.79 $349,980 - $491,021
-27,601 Reduced 14.89%
157,748 $2.54 Million
Q2 2021

Aug 05, 2021
SELL
$12.95 - $15.41 $36,493 - $43,425
-2,818 Reduced 1.5%
185,349 $2.56 Million
Q1 2021

May 06, 2021
BUY
$14.42 - $21.39 $153,616 - $227,867
10,653 Added 6.0%
188,167 $2.75 Million
Q4 2020

Feb 10, 2021
BUY
$16.56 - $18.94 $118,304 - $135,307
7,144 Added 4.19%
177,514 $3.09 Million
Q3 2020

Nov 12, 2020
SELL
$17.41 - $19.89 $201,834 - $230,584
-11,593 Reduced 6.37%
170,370 $3.13 Million
Q2 2020

Aug 13, 2020
BUY
$14.43 - $19.16 $1.15 Million - $1.52 Million
79,478 Added 77.55%
181,963 $3.25 Million
Q1 2020

May 06, 2020
SELL
$11.67 - $22.53 $40,529 - $78,246
-3,473 Reduced 3.28%
102,485 $1.66 Million
Q4 2019

Feb 05, 2020
BUY
$16.33 - $21.37 $61,286 - $80,201
3,753 Added 3.67%
105,958 $1.91 Million
Q3 2019

Oct 23, 2019
SELL
$16.3 - $23.37 $64,482 - $92,451
-3,956 Reduced 3.73%
102,205 $2.07 Million
Q2 2019

Aug 14, 2019
BUY
$13.1 - $22.1 $219,372 - $370,086
16,746 Added 18.73%
106,161 $2.35 Million
Q1 2019

May 01, 2019
BUY
$8.38 - $15.5 $177,354 - $328,042
21,164 Added 31.01%
89,415 $1.22 Million
Q4 2018

Jan 31, 2019
BUY
$8.65 - $16.28 $212,210 - $399,397
24,533 Added 56.12%
68,251 $618,000
Q3 2018

Nov 07, 2018
SELL
$14.45 - $20.25 $19,695 - $27,600
-1,363 Reduced 3.02%
43,718 $721,000
Q2 2018

Aug 06, 2018
BUY
$10.25 - $17.45 $97,877 - $166,630
9,549 Added 26.87%
45,081 $631,000
Q1 2018

May 02, 2018
SELL
$9.1 - $13.7 $6,051 - $9,110
-665 Reduced 1.84%
35,532 $393,000
Q4 2017

Feb 09, 2018
SELL
$8.35 - $14.4 $55,068 - $94,968
-6,595 Reduced 15.41%
36,197 $319,000
Q3 2017

Nov 06, 2017
BUY
$11.1 - $14.5 $474,991 - $620,484
42,792
42,792 $571,000

Others Institutions Holding CHRS

# of Institutions
133
Shares Held
76.9M
Call Options Held
40.7K
Put Options Held
50.1K
View Full List

About Coherus BioSciences, Inc.

CHRS Quotes by TradingView
  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $86.3M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email